Secretin
Also referenced as: ChiRhoStim
A synthetic human peptide hormone used in specialist pancreatic diagnostic procedures.
- Evidence grade
- BModerate Human Evidence
Moderate Human Evidence
- Regulatory status
- FDA Approved for Specific Indication
ChiRhoStim is FDA-approved for specified diagnostic uses, not treatment of autism or general digestive complaints.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A synthetic human peptide hormone used in specialist pancreatic diagnostic procedures.
ChiRhoStim is FDA-approved for specified diagnostic uses, not treatment of autism or general digestive complaints.
A diagnostic pancreatic response does not establish therapeutic benefit for autism or general digestive optimization.
Why It's Being Studied
- Pancreatic diagnostic testing
- Gastrinoma testing
- ERCP
Mechanism of Action
It stimulates pancreatic bicarbonate secretion, enabling physiological responses to be measured.
It stimulates pancreatic bicarbonate secretion, enabling physiological responses to be measured. A diagnostic pancreatic response does not establish therapeutic benefit for autism or general digestive optimization.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Pancreatic diagnostic testing
- Gastrinoma testing
- ERCP
- Intravenous diagnostic medicine
Evidence Summary
Human physiological evidence supports pancreatic function, gastrinoma and selected ERCP diagnostic uses.
Higher tiers carry more weight. Filled tiers have evidence for Secretin; tap to read it.
- Human physiological evidence supports pancreatic function, gastrinoma and selected ERCP diagnostic uses.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Human physiological evidence supports pancreatic function, gastrinoma and selected ERCP diagnostic uses.
Reported Adverse Events in Research
- Nausea, flushing and confounded diagnostic interpretation are possible.
Limitations of Current Evidence
- A diagnostic pancreatic response does not establish therapeutic benefit for autism or general digestive optimization.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Secretin | Trofinetide | |
|---|---|---|
| Evidence grade | B — Moderate Human Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Intravenous diagnostic medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Secretin — prescribing label